Who manufactures Votrient?

GlaxoSmithKline [NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient™ (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer.

Is there a generic drug for Votrient?

Trade Name(s): Votrient Pazopanib is the generic name for the trade drug Votrient.

How much does pazopanib cost?

Votrient 400mg tablets (Novartis Pharmaceuticals UK Ltd)

What type of drug is pazopanib?

Pazopanib is in a class of medications called kinase inhibitors. It works by slowing or stopping the spread of cancer cells.

What is the limitation of use of Votrient?

Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal (GI) stromal tumors has not been demonstrated. VOTRIENT ® (pazopanib) tablets is indicated for the treatment of adults with advanced renal cell carcinoma (RCC).

Who is eligible for financial support for Votrient?

VOTRIENT ® (pazopanib) tablets is indicated for the treatment of adults with advanced renal cell carcinoma (RCC). FINANCIAL SUPPORT FOR ELIGIBLE PATIENTS WITH Advanced Renal Cell Carcinoma (RCC)

When to tell your health care provider about Votrient?

VOTRIENT may cause bleeding problems, which may be severe and cause death. Tell your health care provider before taking VOTRIENT if you have a history of abnormal bleeding. If you experience unusual bleeding, bruising, or wounds that do not heal, call your health care provider right away.

What are the side effects of Votrient tablets?

See “Warnings… + VOTRIENT ® (pazopanib) tablets is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). To learn more about what the Novartis Oncology Patient Support Program can offer your patients, call 1-800-282-7630 or visit www.HCP.Novartis.com/Access/.